Abstract #3814
cPLA2IVA inhibition in basal-like breast cancer: Reduced tumor growth with metabolic, vascular and gene expression changes
Hanna Maja Tunset 1 , Eugene Kim 1 , Jana Cebulla 1 , Muhammad Riyas Vettukattil 1 , Astrid Jullumstr Feuerherm 2 , Berit Johansen 2 , Tone Frost Bathen 1 , and Siver Andreas Moestue 1
1
MR Cancer Group, Department of Circulation
and Medical Imaging, Norwegian University of Science and
Technology, Trondheim, Norway,
2
Avexxin
AS, Department of Biology, Norwegian University of
Science and Technology, Trondheim, Norway
The cPLA2IVA gene PLA2G4A is highly expressed in
aggressive basal-like breast cancer (BLBC) and may be
represent a new therapeutic target. 1H HR MAS MRS, CT,
and gene expression analysis were used to explore the
effect of cPLA2IVA inhibition in BLBC xenografts.
Treatment significantly inhibited tumor growth and
induced early favorable metabolic changes (higher PCho,
lower GPC), intermediate anti-angiogenic effects
(smaller vessels, avascular regions), and late gene
expression changes (up-regulated transcription and
translation, possibly apoptosis). Thus, cPLA2IVA
inhibition may represent a novel strategy for targeted
treatment of BLBC
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Click here for more information on becoming a member.
